CBO Stock Overview

A clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. More details

CBO fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($0)

Does not have a meaningful market cap (€12M)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Imunon, Inc. Competitors

4SC

DB:VSC

€28.4m

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€2.0m

Heidelberg Pharma

XTRA:HPHA

€144.5m

Price History & Performance

Summary of share price highs, lows and changes for Imunon
Historical stock prices
Current Share Price	US$0.73
52 Week High	US$3.70
52 Week Low	US$0.58
Beta	1.75
1 Month Change	-9.32%
3 Month Change	-13.61%
1 Year Change	-39.17%
3 Year Change	-72.76%
5 Year Change	-95.91%
Change since IPO	-99.93%

Recent updates

Shareholder Returns

	CBO	DE Biotechs	DE Market
7D	-1.4%	1.8%	2.5%
1Y	-39.2%	-13.8%	13.4%

Return vs Industry: CBO underperformed the German Biotechs industry which returned -14.9% over the past year.

Return vs Market: CBO underperformed the German Market which returned 15% over the past year.

Price Volatility

Is CBO's price volatile compared to industry and market?
CBO volatility
CBO Average Weekly Movement	11.4%
Biotechs Industry Average Movement	5.9%
Market Average Movement	6.4%
10% most volatile stocks in DE Market	12.9%
10% least volatile stocks in DE Market	3.1%

Stable Share Price: CBO's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: CBO's weekly volatility has decreased from 33% to 11% over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1982	25	Stacy Lindborg	imunon.com

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.

Imunon, Inc. Fundamentals Summary

How do Imunon's earnings and revenue compare to its market cap?
CBO fundamental statistics
Market cap	€10.82m
Earnings (TTM)	-€16.37m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.6x

P/E Ratio

Is CBO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CBO income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$18.62m
Earnings	-US$18.62m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

May 12, 2025

Earnings per share (EPS)	-1.28
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did CBO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/06 10:00
End of Day Share Price	2025/05/06 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Imunon, Inc. is covered by 17 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
James Molloy	Alliance Global Partners
Raymond Deacon	Brean Capital
Kumaraguru Raja	Brookline Capital Markets

CBO Stock Overview

Risk Analysis

Imunon, Inc. Competitors

DB:VSC

€28.4m

XTRA:CNW

€6.5m

XTRA:MDG1

€2.0m

XTRA:HPHA

€144.5m

Price History & Performance

Recent News & Updates

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to Be Published in Gynecologic Oncology

Imunon Announces Imnn-001 Abstract Accepted for Oral Presentation

Imunon, Inc. has filed a Follow-on Equity Offering.

Imunon, Inc. Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Imunon, Inc. Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

Imunon, Inc. to Report Fiscal Year 2024 Results on Feb 27, 2025

Recent updates

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to Be Published in Gynecologic Oncology

Imunon Announces Imnn-001 Abstract Accepted for Oral Presentation

Imunon, Inc. has filed a Follow-on Equity Offering.

Imunon, Inc. Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Imunon, Inc. Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

Imunon, Inc. to Report Fiscal Year 2024 Results on Feb 27, 2025

IMUNON, Inc. Announces Translational Data from Phase 1/2 OVation 2 Study of IMNN-001 in Advanced Ovarian Cancer

Imunon Appoints Douglas V. Faller as Chief Medical Officer, Effective February 18, 2025

IMUNON, Inc. Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

Imunon Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 Ovation 2 Study of Imnn-001

Imunon, Inc. Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

Imunon, Inc. Announces Results from its End-Of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

New major risk - Financial position

IMUNON, Inc. Announces the Presentation of New Clinical Data from the Recently Completed Phase 2 Study of IMNN-001

Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024

IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary

Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million.

Imunon, Inc. announced that it has received $10 million in funding

New major risk - Shareholder dilution

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial

IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024

Imunon, Inc. to Report Q1, 2024 Results on May 13, 2024

Imunon, Inc., Annual General Meeting, Jun 12, 2024

Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101

Imunon, Inc. has withdrawn its Follow-on Equity Offering.

New major risk - Financial position

Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New major risk - Share price stability

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.87 loss in 3Q 2022)

Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer

IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board

Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board

First half 2023 earnings released: US$1.28 loss per share (vs US$2.59 loss in 1H 2022)

New major risk - Financial position

IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

New major risk - Share price stability

Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors

First quarter 2023 earnings released: US$0.68 loss per share (vs US$1.82 loss in 1Q 2022)

Full year 2022 earnings released: US$5.03 loss per share (vs US$3.83 loss in FY 2021)

Imunon, Inc. Announces Separation of Nicholas Borys as Executive Vice President and Chief Medical Officer, Effective as of February 28, 2023

Imunon Appoints Corinne Le Goff as Chief Executive Officer

Imunon, Inc. Announces Board Changes

Third quarter 2022 earnings released: US$0.87 loss per share (vs US$0.94 loss in 3Q 2021)

Imunon Appoints James E. Dentzer to Its Board of Directors

Celsion Corporation Completes Enrollment of the Phase I/Ii Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Provides Update on the Progress Made in the Development of A DNA-Based Vaccine Using its PLACCINE Platform Technology

First half 2022 earnings released: US$2.86 loss per share (vs US$4.26 loss in 1H 2021)

Insufficient new directors

Celsion Corporation Appoints Dr. Corinne Le Goff as President an Director

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

First quarter 2022 earnings released: US$1.82 loss per share (vs US$1.29 loss in 1Q 2021)